Science
Cornell Professors Explain Possible Risks and Benefits of COVID-19 Antiviral Treatment
|
The first-ever COVID antiviral pill developed by Merck could be available before the end of the year. The drug, molnupiravir, has been shown to reduce the risk of hospitalization and death from COVID-19 by 50 percent, and on Oct. 11, Merck requested the Food and Drug Administration for an emergency authorization of the pill.